Introduction
Use of stable isotope labelling of lipid precursors in conjunction with detailed, mass spectrometry-based, lipidomic analyses has yielded powerful methodologies for molecular level analysis of the specificity and dynamics of lipid synthesis in vivo and in vitro Hunt 2009 ). When combined with determination of isotope enrichment within substrate pools these data further permit calculation of absolute flux rates through pathways and even individual molecular species of lipids (Pynn et al 2011) . Such tools, in addition to probing normal developmental, nutritional or pathology-based perturbations in lipid metabolism, can also provide greater insight into unexpected derangements/dysregulations of lipid metabolism that may accompany specific gene targeted modifications.
An illustrative example is provided by surfactant protein D (SP-D), a member of the collectin family of carbohydrate pattern recognition host defence proteins, synthesised and secreted by the lung alveolar epithelium (Persson et al 1988) , but also by many other epithelial surfaces (Madsen et al 2000) . In addition to its ability to opsonise and aggregate bacteria (Kuan et al 1992 , Restrepo et al 1999 and to bind viral particles and fungi (Hartshorn et al 1994 , Schelenz et al 1995 , studies in a variety of SP-D null mice have highlighted an initially unexpected role for SP-D both in the maintenance of the integrity of alveolar structure and in the regulation of pulmonary surfactant phospholipid metabolism. SP-D -/-mice develop a progress emphysema-like destruction of alveolar septa with age characterised by a progressive alveolar lipoproteinosis and the accumulation of large foamy macrophages (Botas et al 1998 , Korfhagen et al 1998 mouse lung tissue and bronchoalveolar lavage (BALF) disaturated phosphatidylcholine (Sat-M a n u s c r i p t PC) has previously been described (Ikegami et al 2000) , with increased labelling of lung tissue PC and accumulation of incorporated label in BALF PC up until 72h incubation.
These results were interpreted as decreased PC catabolism in the SP-D -/-mouse compared with control mouse lungs.
Many studies have used Sat-PC analysis as a surrogate for dipalmitoylphosphatidylcholine (DPPC, PC16:0/16:0), the major surface-tension lowering component of lung surfactant; the fundamental importance of DPPC for optimal function of human lung surfactant was established soon after the identification of surfactant deficiency as the primary cause of respiratory distress syndrome in preterm infants (Avery and Mead 1959, Klaus et al 1961) .
SAT-PC has typically been analysed as the residue after oxidation of surfactant lipid extracts with OsO 4 (Mason et al 1976) . In this experimental approach, OsO 4 complexes with double bonds in the unsaturated PC species leaving disaturated phospholipids as the chloroformsoluble residue. The OsO 4 technique has the advantages of being rapid, amenable to analysis of relatively large numbers of samples and providing a simple result. However, SAT-PC analysis is not specific for DPPC, but also includes other PC species such as palmitoylmyristoyl PC (PC16:0/14:0) (Hunt et al 1991) , which can in turn be a significant surfactant component, for instance in the suckling post-natal rat (Bernhard et al 2007) . This example illustrates the importance of the distribution of individual phospholipid molecular species for studies of surfactant metabolism and function. We have previously demonstrated the usefulness of surfactant phospholipid molecular species molecular species analysis in a variety of respiratory diseases, including asthma (Wright et al 2000) , cystic fibrosis (Postle et al 1999) and paediatric acute lung injury (Todd et al 2010) .
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Numerous studies have detailed the importance of acyl remodelling mechanisms in the synthesis of DPPC (Stymne and Stobart 1985 , Batenburg et al 1978 , Caesar et al 1991 . Up to 50% of lung DPPC is not synthesised directly from diacylglycerol (DAG), but is remodelled from other PC species by the sequential actions of phospholipase and acyltransferase enzymes. These analyses have shown an initial synthesis of unsaturated PC, typically palmitoyllinoleoyl PC (PC16:0/18:2) or palmitoyloleoyl PC (PC16:0/18:1), their subsequent conversion to 1-palmitoyl lysoPC (LPC16:0) by the action of a phospholipase A 2 , followed finally by re-esterification to DPPC by the addition of palmitoyl-CoA, catalysed by lysoPC acyltransferase (LPCAT) (Okuyama et al 1983) . Indeed, the critical importance of LPCAT for surfactant function has recently been highlighted by the demonstration that the null mutation is fatal in neonatal mice (Chen et al 2006) .
One final factor in surfactant metabolism that has rarely been considered in detail is the temporal relationship between mechanisms of phospholipid synthesis and the molecular specificity of surfactant secretion from the type II cell. The assumption of studies which typically involve pre-labelling surfactant PC for 24 hours followed by hormonal stimulus of secretion is that these are linear processes. Their inherent implication is that surfactant PC is synthesised de novo, acyl remodelled and packaged into lamellar bodies to acquire its mature equilibrium composition before lamellar body contents are secreted into the alveolar lumen. 
Materials and methods

Animal labelling
Standard homologous techniques were used to generate mice deficient in SP-D as previously 
ESI-MS analysis of phosphatidylcholine and choline phosphate
Frozen lavaged lungs were homogenised in 3 ml of 0.9% saline using an Ultra-Turrax 
M a n u s c r i p t
The eluates were dried under nitrogen gas and re-suspended in methanol (100μl) A c c e p t e d M a n u s c r i p t
Results
Methyl-9-[ 2 H] choline incorporation into lung and BALF
Choline is incorporated into PC by the CDP:choline pathway, whereby it is converted first to Both spectra have been normalised to the highest abundance ion peak displayed; the respective fractional incorporations are shown below in Figure 2 . Importantly, although newly synthesised and endogenous PC had relatively similar compositions, these were not identical. For example, the proportion of PC16:0/18:2 and PC16:0/18:1 were higher in newly synthesised PC compared with endogenous PC, but there was negligible incorporation into the corresponding stearoyl species (PC18:0/18:2 and PC18:0/18:1).
The fractional incorporations of methyl-9-[ 2 H] choline incorporation into PC were calculated for the sum of the 19 molecular species that individually contributed greater than 1 mole % of total PC. This value was given by equation 1: M a n u s c r i p t
Fractional intensity = (ΣP193 x 100) %, where ΣP193 and ΣP184 are sums of the (ΣP193 + ΣP184) respective ion intensities after correction for 13 C isotope abundance and differential CID fragmentation. Lung fractional incorporation was maximal at 6h for control and at 3h for SP-D -/-mice and then declined by 24h for both groups (Fig 2A) . At all time points, the extent of the fractional enrichment for the SP-D -/-mouse was consistently about half that of control mice (Fig 2A) . Incorporation into BALF PC was measureable by 1.5h and then increased progressively until 24h; enrichment of BALF PC was again much lower in the SP-D -/-compared with control mice at all time points (Fig 2B) . These comparisons are somewhat misleading, however, as total PC concentration in the lavaged SP-D -/-mouse lung was higher than in control mouse lung (2.20±0.69 vs 1.54±0.26 μmoles/lung, n=20, p<0.001), with corresponding values for BALF PC being 0.54±0.22 and 0.26±0.12 μmoles/lavage (p<0.001).
There was proportionally more PC recovered in the lavage fraction in the SP-D -/-mouse (19.95±5.64) than in the control mouse (13.07±3.48 % total lung PC, p<0.001). Taking these differences into account, rates of incorporation/lung of methyl-9-[ 2 H] choline were more comparable between the two groups.
Calculation of lung PC synthesis and turnover
The extent of incorporation of a labelled substrate is the product of the measured enrichment mouse, but an upper value of 0.057 μmoles/lung/h can be estimated from the results between 6 and 24h as a measure of the rate of accumulation of lung PC. This is almost certainly an over-estimate, but illustrates how a relatively small imbalance between synthesis and catabolism is sufficient to account for the slow accumulation of PC in the SP-D -/-mouse lung.
PC secretion and turnover in BALF
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Newly synthesised PC (% total methyl-9-[
2 H] choline incorporation) was detectable in BALF at 1.5h ( Fig 5) ; extrapolation of the data suggested that the lag time for secretion of newly synthesised surfactant PC was just under one hour (mean 0.94h). Initial accumulation of label between 1.5 and 6h was slightly greater for SP-D -/-mice (1.47 % total incorporation/h) than for control mice (1.25 % total incorporation/h), but this difference was not significant until 24h (Fig 5) . These proportions of secreted PC at 24h were comparable to the distributions of endogenous PC in BALF. Correcting this percentage secretion for substrate choline phosphate enrichment, the apparent rates of PC secretion for the first 6h after label administration were identical for SP-D -/-mice (30.6 nmoles/h) and control mice (29.8 nmoles/h) (Fig 6) .
Specificity of surfactant phosphatidylcholine synthesis
In addition to estimates of total PC flux, ESI-MS facilitated the analysis of the molecular specificity of acyl remodelling in surfactant PC synthesis and secretion. M a n u s c r i p t newly-synthesised surfactant PC had to achieve the mature composition before secretion, then all newly synthesised and secreted surfactant PC would have been expected to display the same composition at all time points after label administration, and this was clearly not the case.
Discussion
Total lung phospholipid content of the SP-D -/-mouse has been reported to increase progressively compared with control mice up until at least 18 weeks (Botas et al 1998) (Fig 4) . For control mice, which regulate a constant lung PC concentration, the rate of PC catabolism and/or export must equal this rate of synthesis, giving a turnover time of 3.19h calculated by dividing lung PC concentration by synthetic rate. One consequence of this conclusion is that, for analyses at 6h and 24h, all lung PC was effectively synthesised in the proceeding 3h period. This interpretation is supported by the observation that the total amount of newly synthesised PC (μmole/lung) reached a plateau from 3-24h that was very close to the lung PC concentration calculated from the P184 scan. In contrast, comparable analysis for the SP-D -/-mouse demonstrated that the rates of lung PC synthesis and loss were not at equilibrium (Fig 4) .
M a n u s c r i p t
These calculations also provide novel insights into the relative dynamics of PC turnover in whole lung and in lung surfactant. The rate of PC turnover in BALF in control mice was 9 nmoles/h, while the rate of lung PC turnover was 57 nmoles/h. This observation shows clearly that metabolism of secreted alveolar surfactant makes a relatively minor contribution to the overall loss of newly synthesised PC from the lungs. It is unlikely that phospholipase A 2 -mediated hydrolysis, for instance, is a major contributor to mouse lung PC catabolism, as concentration and incorporation of methyl-9-[ 2 H] choline into lung lysoPC remained low throughout the 24h labelling period (results not shown). The most likely mechanism responsible for loss of newly synthesised PC from the lung is export of PC from the type II pneumocyte into the circulation and/or lymph fluid. This has been reported to be mediated by ABCA1, with ApoA1 as the acceptor , is stimulated to compensate for increased lung PC synthesis and is relatively specific for longer acyl chain unsaturated PC species. The importance of shorter acyl chain length for selection of PC species to be packaged into lamellar bodies and secreted surfactant (Postle et al 2006) is shown clearly by the increased fractional synthesis of PC16:0/16:1 with time. The significance of this mechanism for removal of PC and cholesterol from lung is shown clearly by the elevated lung lipid content and respiratory distress experienced by ABCA1 deficient mice (Bates et al 2005) .
Finally, the pattern of surfactant PC synthesis and secretion into BALF also has important implications for understanding of mechanisms regulating the molecular specificity of surfactant PC composition. The importance of acyl remodelling mechanisms in the synthesis of surfactant PC16:0/16:0 has long been appreciated (Okuyama et al 1983) , and redistribution with time of the incorporated methyl-9-[ 2 H] choline headgroup from an initially synthesised unsaturated PC towards PC16:0/16:0 was indeed observed as expected in both SP-DA c c e p t e d M a n u s c r i p t control mice (results not shown). The novel and significant observation here (Fig 7) was that a similar redistribution of headgroup methyl-9-[ 2 H] choline label was also observed for both groups of mice. This demonstrates that newly-synthesised PC is rapidly packaged into lamellar bodies and secreted into the alveolus before acyl remodelling processes are complete, in agreement with our previous analysis of the specificity of methyl-9-[ 2 H] choline incorporation into induced sputum PC in adult human volunteers (Bernhard et al 2004) . The fundamental implication from this observation is that assembly of PC in lamellar bodies followed by secretion is not a completely linear process.
The rapid synthesis and turnover of total PC in mouse lung is characteristic of a biological system with a requirement to respond rapidly to altered physiological conditions. As with enzyme protein turnover (Walker 1983) , rapid degradation with a high turnover is a prerequisite for the lungs to be able to increase surfactant PC synthesis rapidly in response, for instance, to alveolar stretch (Torday and Rehan 2002) . Moreover, this analysis suggests that M a n u s c r i p t M a n u s c r i p t (29.8-x) and extrapulmonary transport must balance at equilibrium. Since PC synthesis is >10 x alveolar turnover (520 nmoles/lung/h vs 29.8 nmoles/lung/h), export of excess PC is essential. Observed PC saturation may result in part from selective export of unsaturated PC. Implicit in this model is a recognition that lung is a significant extrahepatic source of circulating, PUFA-enriched PC.
